Found 60 articles
Codagenix Announces Presentation of Updated Preclinical CodaLytic™ Data at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Codagenix Inc. today announced the presentation of preclinical data for CodaLytic™, a codon-modified virus being developed for breast cancer immunovirotherapy, at the Society for the Immunotherapy of Cancer (SITC) 38th Annual Meeting being held virtually and in-person November 1-5, 2023 in San Diego, California.
Codagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue Vaccine
Codagenix Inc. today announced that the US Department of Defense (DoD), through the US Army Medical Research and Development Command and the US Army Medical Research Acquisition Activity, has awarded the Company $5.88 million to advance the development of its CodaVax-DENV, a tetravalent live attenuated dengue vaccine program.
Persephone Biosciences Inc. today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors.
Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv™ at IDWeek 2023
Codagenix Inc. announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.
Codagenix Announces BARDA Contract for Project NextGen Supporting Development of CoviLiv™ as an Intranasal COVID-19 Vaccine
Codagenix Inc. announced that the BARDA has entered into a contract with Codagenix to support the costs of a Phase 2b clinical study of CoviLiv™ for the prevention of symptomatic COVID-19 in people who have completed their primary approved/authorized COVID-19 vaccine series and their last COVID-19 vaccine was at least 3 months beforehand.
Champions Oncology Announces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023
Champions Oncology, Inc. kicks-off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26th.
Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV Vaccine, CodaVax™- RSV, in a Pediatric Population
Codagenix Inc. today announced that it has initiated dosing in a pediatric Phase 1 study evaluating CodaVax™-RSV, a live-attenuated, intranasal vaccine candidate for the prevention of disease caused by respiratory syncytial virus (RSV).
Codagenix Inc. today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.
As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession.
Codagenix Inc. today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.
Codagenix Inc. announced that Paul Grint, MD, has been appointed Chairman of the Board of Directors.
Codagenix Receives FDA Fast Track Designation for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV
Codagenix Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV).
Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines
Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, in collaboration with the Serum Institute of India Pvt. Ltd., today announced dosing has been initiated in an international, multi-center, randomized placebo-controlled Phase 3 clinical trial of CoviLiv.
Codagenix Announces Award with the US Department of Defense for Development of Balanced, Tetravalent Dengue Vaccine
Codagenix Inc. today announced the Department of Defense has granted the company a $4.4 million award to progress development of CodaVax-DENV, its next-generation tetravalent dengue vaccine candidate.
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.
Codagenix Inc. today announced that it has completed dosing of its Phase 1 clinical trial to evaluate CodaVax™-H1N1, a universal, live-attenuated influenza vaccine.
Codagenix, Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that company leadership will present at the upcoming 2022 Jefferies Healthcare Conference, taking place in New York City, June 8-10, 2022.
Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV
Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV.
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Codagenix Inc. today announced the first patient has been dosed in a U.K.-based Phase 1 clinical trial to evaluate the use of Codagenix's novel intranasal, live-attenuated virus vaccine, CoviLiv™, as a booster in healthy adults following prior vaccination with approved COVID-19 vaccines.